Want to see HK:2410 full AI Analyst Report?
2410 Stock Chart & Stats
HK$12.93
-HK$7.80(-21.14%)
At close: 4:00 PM EST
HK$12.93
-HK$7.80(-21.14%)
Day’s Range― - ―
52-Week RangeHK$5.35 - HK$22.56
Previous CloseN/A
Volume117.00K
Average Volume (3M)14.02M
Market Cap
HK$2.59B
Enterprise ValueHK$4.70K
Total Cash (Recent Filing)HK$158.31M
Total Debt (Recent Filing)HK$120.72M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding380,065,830
10 Day Avg. Volume4,737,687
30 Day Avg. Volume14,019,805
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)15.38
Price to Sales (P/S)0.00
P/FCF Ratio-17.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.78
Revenue Forecast (FY)HK$504.00M
Bulls Say, Bears Say
Bulls Say
Narrowing Cash BurnThe company reduced cash outflows and narrowed losses in 2025 versus 2024. This durable improvement extends operational runway, lowers immediate refinancing pressure, and gives management more time to advance clinical programs or achieve milestone-based funding over the next several months.
Improving CapitalizationPositive equity and a moderate debt-to-equity ratio provide a structural cushion versus peers with negative equity. The stronger capital position and declining total debt in 2025 support solvency, enabling access to financing and preserving operational flexibility across the medium term.
Evidence Of Cost ControlA narrowed net loss implies management has implemented cost controls that are reducing burn. Sustained expense discipline can materially extend runway, improve incremental margins on any future revenue, and demonstrate operational competence relevant over the next 2–6 months.
Bears Say
Minimal / No Revenue BaseThe company lacks a material revenue stream, leaving it unable to self-fund operations. Absent commercialization or recurring income, the firm remains structurally dependent on external capital or milestone payments, a material medium-term execution and financing risk.
Large Persistent Losses And Cash BurnHeavy recurring losses and negative operating/free cash flow will erode resources without new funding or revenue. This structural cash consumption constrains R&D investment choices, increases dilution risk, and limits strategic optionality over the next several quarters.
Fragile Capital History And Funding RiskA history of negative equity and significant declines in shareholders' equity indicates a fragile capital structure. That history raises the probability of future dilution or restructuring if operating losses persist, creating persistent funding risk until revenue or sustained profitability emerges.
TYK Medicines, Inc. Class H News
2410 FAQ
What was TYK Medicines, Inc. Class H’s price range in the past 12 months?
TYK Medicines, Inc. Class H lowest stock price was HK$5.35 and its highest was HK$22.56 in the past 12 months.
What is TYK Medicines, Inc. Class H’s market cap?
TYK Medicines, Inc. Class H’s market cap is HK$2.59B.
When is TYK Medicines, Inc. Class H’s upcoming earnings report date?
TYK Medicines, Inc. Class H’s upcoming earnings report date is Aug 17, 2026 which is in 7 days.
How were TYK Medicines, Inc. Class H’s earnings last quarter?
TYK Medicines, Inc. Class H released its earnings results on Mar 30, 2026. The company reported -HK$0.545 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is TYK Medicines, Inc. Class H overvalued?
According to Wall Street analysts TYK Medicines, Inc. Class H’s price is currently Overvalued.
Does TYK Medicines, Inc. Class H pay dividends?
TYK Medicines, Inc. Class H does not currently pay dividends.
What is TYK Medicines, Inc. Class H’s EPS estimate?
TYK Medicines, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TYK Medicines, Inc. Class H have?
TYK Medicines, Inc. Class H has 380,065,830 shares outstanding.
What happened to TYK Medicines, Inc. Class H’s price movement after its last earnings report?
TYK Medicines, Inc. Class H reported an EPS of -HK$0.545 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.182%.
Which hedge fund is a major shareholder of TYK Medicines, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2410
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TYK Medicines, Inc. Class H Stock Smart Score
Company Description
TYK Medicines, Inc. Class H
TYK Medicines, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, obtaining, advancing, and bringing to market innovative treatments for significant unmet needs in oncology. The company's primary drug candidate, TY-9591, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is being developed to treat non-small cell lung cancer (NSCLC) with EGFR mutations that has metastasized to the brain, as well as locally advanced or metastatic NSCLC characterized by the EGFR L858R mutation. Beyond its lead candidate, TYK Medicines maintains a diverse pipeline of other investigational therapies. These include TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor designed for solid tumors such as breast and prostate cancer. Another compound, TY-2136b, is an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor also aimed at solid tumors. The company is advancing TY-2699a, a selective CDK7 inhibitor, and TY-0540, a selective CDK2/4/6 inhibitor, both targeting advanced or metastatic solid malignancies. Further, the pipeline features TY-4028, an oral exon 20 insertion tyrosine kinase inhibitor (TKI) specifically addressing locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 or HER2 exon 20 insertions. TY-1091 is a potent and selective rearranged during transfection proto-oncogene (RET) inhibitor, under development for advanced NSCLC with RET gene fusion, advanced medullary thyroid cancer with RET gene mutation, and other solid tumors presenting RET gene alterations. Other promising programs include TY-1054, an oral yes-associated protein-transcriptional enhanced associate domain inhibitor for various cancers; TY-1210, a selective CDK2 inhibitor for solid tumors; TY-0609, a selective CDK4 inhibitor also for cancer therapy; and TY-3200, an innovative EGFR degrader. Established in 2017, the enterprise operates from its main office located in Huzhou, China.
Technical Analysis
Peijia Medical Ltd.
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Viva Biotech Holdings
―
Clover Biopharmaceuticals Ltd.
―
Jacobson Pharma Corporation Limited
―